Nano-mAbs - Radioactive Drugs

• Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation
• The product is paired with a diagnostic, using the same antibody vector but labelled with a lower radiation radioisotope for imaging
• Initial targets are HER-2, TROP-2 and PD-L1

99mTc-HER-2 Imaging In Breast Cancer
Uptake of 99mTc-HER-2 was also observed in nodal and distant metastatic lesions in multiple pelvic bones and lungs of a HER2 IHC positive patient with excellent conspicuity to background.  Metastatic disease was confirmed with CT scan.

Patient: Male, 75 years old, chest x-ray showed lung shadow. CT scan confirmed multiple lesions. Biopsy confirmed squamous cell carcinoma, a lower left lobe lung hilar tumour, 44 x 48 mm is size with multiple metastases, nodal and distant. 99mTc-NM-01 scan results had uptake in primary tumour and multiple metastatic lesions, a strong positive image. PD-L1 IHC likely understated PD-L1 expression for this patient, PD-L1 treatment prognosis for such a patient is expected to be favourable, though further investigation is required.